BY OUR PLATFORMS
BY THERAPEUTIC AREA
Carles Cornet - 16 November 2022
Combining a zebrafish-based high throughput platform with artificial intelligence for human developmental toxicity assessment.
Miriam Martínez - 13 October 2022
Zebrafish contribution to drug development reaching clinical stages
Javier Terriente - 15 September 2022
AI can address many challenges and limitations in traditional R&D and offer value in drug discovery in multiple ways.
Miriam Martínez - 27 July 2022
Zebrafish for regulatory purposes in ecotoxicology and safety pharmacology
Miriam Martínez - 30 June 2022
New trends and updated availability for zebrafish studies in EU and US
Carles Cornet - 11 May 2022
Why zebrafish can pave the way for investigating epilepsy’s etiology and screening new anti-seizure drugs
Miriam Martínez - 16 March 2022
How to choose which type of experiment is best-suited for my research?
Javier Terriente - 19 January 2022
Use of biomarkers in endocrine disruption compounds screening and testing with zebrafish
Vincenzo Di Donato - 24 November 2021
Leveraging zebrafish to study Age-related Macular Degeneration
Christian Cortés - 20 September 2021
The emerging use of zebrafish to model metabolic diseases
Miriam Martínez - 21 July 2021
Are zebrafish suitable for human drug discovery?
Nicolás Palanca - 28 June 2021
The regulatory status of zebrafish as an alternative preclinical model.
Sylvia Dyballa - 12 May 2021
In ZeClinics we bet on emerging technologies to scale our solutions.
Sergio Jarque - 10 March 2021
From challenge to knowledge: the outstanding performance of zebrafish in predicting toxicity.
Flavia de Santis - 10 February 2021
ZeClinics can do it by using different genome editing approaches.
Vincenzo Di Donato - 13 January 2021
ZeClinics laboratory R&D efforts are mainly divided in the development of three research platforms including a number of research areas.
Javier Terriente - 02 December 2020
We knew the model was brilliant for academic research. Would it be as good for modeling human disease and discovering new drugs in an industrial setting?